pharmacopeia

Mechanism of action

Sourced from openFDA

Mechanism-of-action class: Protein Synthesis Inhibitors.

Protein Synthesis

Indications

Sourced from openFDA
  • Use first aid to help prevent infection in minor scrapes, cuts, and burns

Dosage & administration

Sourced from openFDA

Directions clean affected area apply a small amount 1 to 3 times daily may cover with a sterile bandage

Warnings & precautions

Sourced from openFDA

For external use only Do not use in eyes over large areas of the body or on puncture wounds, animal bites or serious burns for more than 1 week unless directed by a doctor if you are allergic to any of the ingredients Stop use and ask a doctor if a rash or allergic reaction develops condition worsens or persists Keep out of reach of children If ingested, contact a Poison Control Center right away.

Approval history

Sourced from openFDA
  • May 17, 1962NDANDA050356Ph Health
  • Jun 6, 1963NDANDA050023Harrow Eye
  • Jun 11, 1963ANDAANDA060700Eurofarma
  • Jul 19, 1963NDANDA050065Sandoz
  • Sep 2, 1964ANDAANDA060304Teva
  • May 25, 1975NDANDA060613Casper Pharma Llc
  • Aug 25, 1983ANDAANDA062423Sandoz
  • May 22, 1984ANDAANDA062341Sandoz

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
6,477 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Drug Ineffective91414%
  2. 2Drug Hypersensitivity90014%
  3. 3Pain84413%
  4. 4Malaise80512%
  5. 5Off Label Use78812%
  6. 6Rash78012%
  7. 7Vomiting75312%
  8. 8Infusion Related Reaction74411%
  9. 9Pyrexia72911%
  10. 10Fatigue72611%
  11. 11Dyspnoea71711%
  12. 12Type 2 Diabetes Mellitus66910%
  13. 13Nausea66810%
  14. 14Swelling65010%
  15. 15Systemic Lupus Erythematosus6289.7%

Literature

View JSON

Recent PubMed references pinned to Neomycin as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 78 ClinicalTrials.gov registrations naming Neomycin as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Pharmacogenomics

View JSON

CPIC-curated drug–gene pairs for Neomycin. Levels describe the strength of curated evidence and guideline status — never a recommendation to test or to adjust therapy.

Frequently asked questions

How does Neomycin work?
Mechanism-of-action class: Protein Synthesis Inhibitors.
What is Neomycin used for?
According to FDA labeling, Neomycin carries indications including: Use first aid to help prevent infection in minor scrapes, cuts, and burns. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Neomycin?
Neomycin is classified as Antibiotics, Antiinfectives, Antiinfectives and antiseptics for local oral treatment, Other aminoglycosides, Other antibiotics for topical use, Aminoglycoside Antibacterial, Protein Synthesis Inhibitors, Decreased Protein Synthesis.
What are the brand names for Neomycin?
Neomycin is marketed under brand names including Cortisporin, Cortisporin-TC, Cuadriderma, Lanabiotic, Maxitrol, Mycitracin Plus Pain Reliever, Neo-Polycin, Neo-Polycin HC.
Note. Data for neomycin is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients